MMJ Observer
Tag Archives: NASDAQ:INSY

The charges against several executives of Insys Therapeutics Inc (NASDAQ:INSY) discussed in the DOJ PR relate to initially disclosed probe. The company is cooperating with all relevant authorities in ongoing investigations and is dedicated to...

By Sophia T on Dec 28th, 2016

Much has been inferred of the market prospect for “Epidiolex” from GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH). All the merited delight over the “Epidiolex” potential in the cure of childhood epilepsies has blinded the...

By Emily Gibson on Dec 15th, 2016
insys-therapeutics-inc

Insys Therapeutics Inc (NASDAQ:INSY) has recently released its third quarter earnings report. Q3 Financial Results The company had a net revenue of $55.20 million, down by 39.50% year-over-year from $91.30 million. Insys Therapeutics had sales...

By Jaime Williams on Dec 2nd, 2016

Insys Therapeutics Inc (NASDAQ:INSY), better known for its pharmaceutical offerings, is in deep trouble after its top management executives have been found involved in off-label and illegal marketing of Subsys. It’s one of the core products...

By Steven Russell on Feb 18th, 2016

In a recent public statement, Wolf Haldenstein Adler Freeman & Herz LLP announced that Insys Therapeutics Inc (NASDAQ:INSY) was facing class action for indulging into illegal and off-label marketing activities to promote its core product....

By Steven Russell on Feb 16th, 2016

Last few months have thrown a lot of challenges towards Insys Therapeutics Inc (NASDAQ:INSY) in the form of lawsuit charges and negative marketing; however, it looks forward to dealing with them effectively. To start with, it has decided to...

By Sophia T on Feb 11th, 2016